Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$224.66 USD

224.66
1,906,786

-2.27 (-1.00%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $224.54 -0.12 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of -62.75% and 8.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

by Zacks Equity Research

Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.

Zacks Equity Research

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Illumina (ILMN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sundeep Ganoria headshot

Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings

by Sundeep Ganoria

Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.

Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sundeep Ganoria headshot

3 Unconventional Cannabis Stocks to Watch in 2025

by Sundeep Ganoria

Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.

Supriyo Bose headshot

Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak

by Supriyo Bose

CBOE, AGNC, JAZZ, AES and CNSWF are some of the stocks with high ROE to profit from as markets expect the tariff war to end soon.

Sundeep Ganoria headshot

Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?

by Sundeep Ganoria

Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.

Zacks Equity Research

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

by Zacks Equity Research

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.